Publication:
Aberrant DNA methylation of SOCS1 gene is not associated with resistance to imatinib mesylate among chronic myeloid leukemia patients

Simple item page
dc.Chemicals/CAScytosine, 71-30-7; imatinib, 152459-95-5, 220127-57-1; uracil, 66-22-8; Imatinib Mesylate; SOCS1 protein, human; Suppressor of Cytokine Signaling 1 Protein
dc.FundingDetailsUniversiti Teknologi MARA,�UiTM Hospital Universiti Sains Malaysia,�HUSM 1001/PPSP/812070 Universiti Sains Malaysia,�USM
dc.FundingDetailsThis study was supported by Universiti Sains Malaysia � Research University Grant (USM-RU) 1001/PPSP/812070. Exceptional appreciation to Dr. Hoh Boon Peng and staff of Institute of Medical Molecular Biotechnology (IMMB), Faculty of Medicine, Universiti Teknologi MARA for the facilities used in this study. The co-operation and support of staff, Human Genome Center, Universiti Sains Malaysia and all the patients who have participated in this study are also gratefully acknowledged.
dc.ManufacturersBiorad, United States; Zymo Research, United States
dc.TradenamesCFX 96, Biorad, United States; EZ DNA, Zymo Research, United States
dc.contributor.affiliationsFaculty of Medicine and Health Sciences
dc.contributor.affiliationsUniversiti Sains Islam Malaysia (USIM)
dc.contributor.affiliationsHospital Universiti Sains Malaysia
dc.contributor.affiliationsInternational Medical University
dc.contributor.affiliationsUniversiti Sains Malaysia (USM)
dc.contributor.authorElias M.H.en_US
dc.contributor.authorAzlan H.en_US
dc.contributor.authorBaba A.A.en_US
dc.contributor.authorAnkathil R.en_US
dc.date.accessioned2024-05-28T08:43:19Z
dc.date.available2024-05-28T08:43:19Z
dc.date.issued2018
dc.description.abstractBackground: In exploring the cause of Imatinib Mesylate (IM) resistance among Chronic Myeloid Leukemia (CML) patients who do not harbor BCR-ABL dependent mechanism, BCR-ABL independent pathways are the most probable pathways that should be explored. In BCR-ABL independent pathway, SOCS1 plays an important role as it helps in regulating optimal JAK/STAT activity. Objective: To identify the association of SOCS1 gene hypermethylation in mediating IM Resistance. Method: The SOCS1 promoter methylation level of 92 BCR-ABL non mutated IM resistant CML patients, 83 IM good response CML patients and 5 normal samples from healthy individuals were measured using Methylation Specific-High Resolution Melt (MS-HRM) analysis. Results: Both primers used to amplify promoter region from-333 to-223 and from-332 to-188 showed less than 10% methylation in all CML and normal samples. Consequently, there was no significant difference in SOCS1 promoter methylation level between IM resistant and IM good response patients. Conclusion: SOCS1 promoter methylation level is not suitable to be used as one of the biomarkers for predicting the possibility of acquiring resistance among CML patients treated with IM. � 2018 Bentham Science Publishers.en_US
dc.description.natureFinalen_US
dc.identifier.doi10.2174/1871529X18666180419101416
dc.identifier.epage238
dc.identifier.issn1871529X
dc.identifier.issue3
dc.identifier.pmid29669505
dc.identifier.scopus2-s2.0-85055076182
dc.identifier.spage234
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85055076182&doi=10.2174%2f1871529X18666180419101416&partnerID=40&md5=5075fbe793fffe3ebcfab489bea84757
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/9346
dc.identifier.volume18
dc.languageEnglish
dc.language.isoen_USen_US
dc.publisherBentham Science Publishers B.V.en_US
dc.relation.ispartofCardiovascular and Hematological Disorders - Drug Targets
dc.sourceScopus
dc.subjectChronic myeloid leukemiaen_US
dc.subjectCytokine signaling tumouren_US
dc.subjectHigh resolution melt analysisen_US
dc.subjectImatinib mesylateen_US
dc.subjectMethylationen_US
dc.titleAberrant DNA methylation of SOCS1 gene is not associated with resistance to imatinib mesylate among chronic myeloid leukemia patientsen_US
dc.title.alternativeCardiovasc. Hematol. Disord. Drug Targetsen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Collections

Scopus